Xortx Therapeutics Stock Cash And Equivalents
XRTX Stock | 1.73 0.15 7.98% |
XORTX Therapeutics fundamentals help investors to digest information that contributes to XORTX Therapeutics' financial success or failures. It also enables traders to predict the movement of XORTX Stock. The fundamental analysis module provides a way to measure XORTX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XORTX Therapeutics stock.
XORTX | Cash And Equivalents |
XORTX Therapeutics Company Cash And Equivalents Analysis
XORTX Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
XORTX Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for XORTX Therapeutics is extremely important. It helps to project a fair market value of XORTX Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since XORTX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XORTX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XORTX Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition |
In accordance with the recently published financial statements, XORTX Therapeutics has 0.0 in Cash And Equivalents. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The cash and equivalents for all Canada stocks is 100.0% higher than that of the company.
XORTX Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of XORTX Therapeutics from analyzing XORTX Therapeutics' financial statements. These drivers represent accounts that assess XORTX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XORTX Therapeutics' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 8.0M | 10.1M | 11.3M | 134.3M | 5.7M | 5.5M | |
Enterprise Value | 7.8M | 10.1M | 11.2M | 123.9M | 2.3M | 2.2M |
XORTX Fundamentals
Return On Equity | -0.29 | ||||
Return On Asset | -0.33 | ||||
Current Valuation | 2.45 M | ||||
Shares Outstanding | 3.22 M | ||||
Shares Owned By Insiders | 3.01 % | ||||
Shares Owned By Institutions | 6.03 % | ||||
Number Of Shares Shorted | 8.82 K | ||||
Price To Book | 1.87 X | ||||
EBITDA | (3.3 M) | ||||
Net Income | (2.16 M) | ||||
Total Debt | 825.94 K | ||||
Book Value Per Share | 2.32 X | ||||
Cash Flow From Operations | (6.58 M) | ||||
Short Ratio | 0.97 X | ||||
Earnings Per Share | 0.17 X | ||||
Target Price | 81.0 | ||||
Beta | -0.21 | ||||
Market Capitalization | 5.58 M | ||||
Total Asset | 5.47 M | ||||
Retained Earnings | (17.85 M) | ||||
Working Capital | 3.77 M | ||||
Net Asset | 5.47 M |
About XORTX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XORTX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XORTX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XORTX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.